Home › Studies › PRJNA918651
PRJNA918651 SRP416001

Gut microbiome in MPN patients on Mediterranean diet, USA

Characterizing the microbiome of patients with myeloproliferative neoplasms during a Mediterranean diet intervention

114 gut metagenome samples from adults and elderly individuals with myeloproliferative neoplasms in California, USA, collected during a 15-week dietary intervention trial comparing Mediterranean diet counseling to standard US dietary guidelines. machine-written summary

103 samples · 114 runs · US · Adult · 2023 · 0.77 Gbp / sample · cohort The NUTRIENT Trial (NUTRitional Intervention among

Sources
✓Sequence archive 824○Abstract / description○Full text✓Supplementary tables 400–External resources–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave
✓ Sequence archive824 sample values (collection date, country, health condition, health condition detail, latitude, location region, longitude, subject id)
○ Abstract / descriptionread; no usable statement
○ Full textread; no usable statement or table · PMC10746218, PMC10913729
✓ Supplementary tables400 sample values (age, bmi, sex, timepoint)
– External resourcesnot covered by the external resources we ingest
– User contributionnothing uploaded yet
– Human verifiednot yet checked by a person · I checked this project — verify it
Interventions

intervention — arms not resolved

Controlled / prescribed diet or feeding regimen design randomized_controlled_trial · population other_disease · Mediterranean diet counseling vs USDA diet, 15 weeks

“Mediterranean or standard 2020 US Guidelines for Americans dietary counseling” — abstract:37877698 (study level; per-sample arms are in the intervention column below)

Samples at a glance
1 sampling locations · 1 country
Age
adult59
elderly44
Condition
other_cancer103
Sex
female72
male28
Country
US103
Body site
primary103
Sequencing depth per sample · this project all projects
all projects, 0–0.03 Gbp: 25,080 samples (4 %)this project, 0–0.03 Gbp: 1 samplesall projects, 0.03–0.1 Gbp: 17,066 samples (3 %)all projects, 0.1–0.3 Gbp: 29,179 samples (5 %)this project, 0.1–0.3 Gbp: 1 samplesall projects, 0.3–1 Gbp: 47,044 samples (8 %)this project, 0.3–1 Gbp: 100 samplesall projects, 1–3 Gbp: 124,983 samples (22 %)this project, 1–3 Gbp: 1 samplesall projects, 3–10 Gbp: 253,728 samples (44 %)all projects, 10–30 Gbp: 72,533 samples (13 %)all projects, 30–100 Gbp: 3,024 samples (1 %)all projects, 100–300 Gbp: 106 samples (0 %)all projects, ≥ 300 Gbp: 9 samples (0 %)project median 0.79 Gbp per sample0130Gbp
Sampling design and relatedness

longitudinal — not resolved

Schedule stated by the source: “stool at weeks 1, 6, 9, and 15” (time origin: enrolment); stated follow-up 3 mo.

How longitudinal and relatedness information is derived

Community composition
Faecalibacterium 7.9%Bacteroides 7.2%Phocaeicola 6.5%Blautia_A 5.6%Alistipes 4.2%Prevotella 3.8%Roseburia 3.6%Bifidobacterium 2.7%Gemmiger 2.4%Ruminococcoides 2.0%Akkermansia 1.6%Lachnospira 1.4%not assigned to a genus 14.4%other genera 36.8%

Genera, mean relative abundance over 95 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).

Field coverage
fieldsamplescoverageR1R2R3R4
age_category103 100%
country103 100%103
health_condition103 100%103
subject_id103 100%103
collection_date103 100%103
detailed_location103 100%
health_condition_detail103 100%103
latitude103 100%103
location_region103 100%103
longitude103 100%103
age_at_collection_days100 97%100
bmi100 97%100
sex100 97%100
timepoint_label100 97%100
Papers (2)
  • Characterizing the microbiome of patients with myeloproliferative neoplasms during a Mediterranean diet intervention. 2023 PMID 37877698 PMC10746218 own_data
  • The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence. 2024 PMID 38391189 PMC10913729 unsure
Details
Archive description

Myeloproliferative neoplasms (MPN) are a class of hematological malignancies which result in the overproduction of myeloid lineage cells. These malignancies result in increased cytokine production and inflammation, which correlate with worsened symptom burden and prognosis. Other than bone marrow transplantation, there is no cure for myeloproliferative neoplasms. As such, treatments focus on reducing thrombotic risk, inflammation, and symptom burden. Because current pharmacological treatments carry significant side-effects, there is a need to explore low-risk therapies. One alternative is the Mediterranean diet, which is rich in anti-inflammatory foods, reduces inflammatory biomarkers, and beneficially alters the gut microbiome. Here, we performed a 15-week clinical trial of 28 individuals with MPN who were randomized to dietary counseling based on either a Mediterranean diet or standard U.S. Guidelines for Americans. Our primary objective was to determine if MPN patients were able to adopt a Mediterranean eating style when supported with dietician counseling. As exploratory endpoints, we investigated the impact of diet and inflammation on the gut microbiome. Using shotgun metagenomic sequencing, we found that microbiome diversity and composition were stable throughout the study duration in both cohorts. Furthermore, we discovered significant differences in the microbiomes between MPN subtypes, such as increased beta-dispersion in subjects with myelofibrosis. Lastly, we found several significant correlations between the abundances of multiple bacterial taxa and cytokine levels. Together, this study provides insight into the interaction between diet, inflammation, and the gut microbiome.

How this project entered the registry

Classified as human gut / stool shotgun DNA metagenome of adult by sonnet_x2 with confidence 0.75. Assay shotgun_dna.

  • host run.host_tax_id · “9606”
  • body site run.scientific_name · “gut metagenome”
  • life stage study.description · “28 individuals with MPN who were randomized”
Evidence examples (one per field × route)
samplefieldvaluerouteconf.sourcequote
SAMN32601121age_at_collection_days25933R20.85paper.supp.mbio.02308-23-s0002.csv[!Age]71
SAMN32601121bmi30.0R20.85paper.supp.mbio.02308-23-s0002.csv[!BMI]30
SAMN32601121collection_date2020-09-30R10.90biosample.attribute:collection_date2020-09-30
SAMN32601121countryUSR10.90sample.attr.geo_loc_nameUSA: California
SAMN32601121health_conditionother_cancerR10.85biosample.attribute:env_broad_scalehuman gut
SAMN32601121health_condition_detailhuman gutR10.85biosample.attribute:env_broad_scalehuman gut
SAMN32601121latitude33.4700R10.90biosample.attribute:lat_lon33.47 N 117.53 W
SAMN32601121location_regionCaliforniaR10.85biosample.attribute:geo_loc_nameUSA: California
SAMN32601121longitude-117.5300R10.90biosample.attribute:lat_lon33.47 N 117.53 W
SAMN32601121sexmaleR20.85paper.supp.mbio.02308-23-s0002.csv[!Sex]M
SAMN32601121subject_idFEA02-1R10.85sample.attr.unique_idFEA02-1
SAMN32601121timepoint_label1R20.85paper.supp.mbio.02308-23-s0002.csv[!week]1
Sequencing

114 runs over 103 samples · mean 0.70 Gbp per run (median 0.77 Gbp, total 79.28 Gbp; 114 runs with a base count) · layout PAIRED 114 · platform ILLUMINA 114 · models Illumina HiSeq 4000 (114) · 86% of runs with a Sandpiper profile · first public 2023-10-20

Authors (22)

Avelar-Barragan J first · Mendez Luque LF · Nguyen J · Nguyen H · Odegaard AO · Fleischman AG · Whiteson KL last · Soyfer EM · Liu J · Chen JH · Mehrotra N · Huang X · Kosiorek HE · Dueck A · Himstead A · Heide E · Lem M · El Alaoui K · Mas E · Scherber RM · Mesa RA · Odegaard A

Downloads

PRJNA918651.csv.gz (3.7 KB) · parquet (75.6 KB) — all 103 samples, every field with route and confidence · PRJNA918651_determinations.csv.gz (8.1 KB) — 1,224 evidence rows

Samples (103 · every field this project has values for · hover a cell for its source)
Loading the sample table…